YD Bio Limited (NASDAQ:YDES – Get Free Report)’s share price was up 3.1% during trading on Wednesday . The company traded as high as $3.32 and last traded at $3.0320. Approximately 22,050 shares changed hands during mid-day trading, an increase of 76% from the average daily volume of 12,558 shares. The stock had previously closed at $2.94.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded YD Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, YD Bio has a consensus rating of “Sell”.
Get Our Latest Stock Report on YDES
YD Bio Price Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC lifted its position in YD Bio Limited (NASDAQ:YDES – Free Report) by 10.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 58,363 shares of the biotechnology company’s stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned about 0.08% of YD Bio worth $711,000 as of its most recent SEC filing.
About YD Bio
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Further Reading
- Five stocks we like better than YD Bio
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for YD Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YD Bio and related companies with MarketBeat.com's FREE daily email newsletter.
